Top Medicare Prescribers Rake In Speaking Fees From Drugmakers

by Charles Ornstein, Tracy Weber and Jennifer LaFleur  |  ProPublica, June 25, 2013, This story was co-published with NPR.   When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics.  So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic’s success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic — even though the drug hadn’t proved more effective than competitors.  The strategy worked. In the 2012 fiscal year, sales of Bystolic reached $348 million, almost double its total from two years earlier, the company reported.  Read more